StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Lumigan/Ganfort (bimatoprost) by Quarter

Lumigan/Ganfort (bimatoprost) — U.S. reported growth YoY (%) (%)

QuarterlyAnnual

AbbVie Lumigan/Ganfort (bimatoprost): -19.0% in Q4 2025, down 102.9 pts from a year earlier.

Latest, Q4 2025
-19.0%
Period ended Dec 31, 2025
Change on a year earlier
-102.9 pts
83.9% in Q4 2024
History
17 quarters
Since Q3 2021
Sources
17
Documents cited below

Where the Q4 2025 figure comes from

“|| Lumigan/Ganfort | 47 | 57 | 104 | (19.0) | (6.6) | (12.6) | (9.1) | (13.9)”

Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗

Reported in Form 8-K Key Product Revenues Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLumigan/Ganfort (bimatoprost) — U.S. reported growth YoY (%) (%)Year on yearSource
Q4 2025Dec 31, 2025-19.0%-102.9 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 2025-26.1%–Form 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 202519.9%+35.7 ptsForm 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 202569.2%+124.2 ptsForm 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 202483.9%+128.0 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q2 2024Jun 30, 2024-15.8%-2.7 ptsForm 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 2024-55.0%-48.2 ptsForm 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 2023-44.1%-22.0 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 2023-53.0%-48.6 ptsForm 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 2023-13.1%+4.3 ptsForm 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 2023-6.8%-8.3 ptsForm 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 2022-22.1%-28.3 ptsForm 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
Q3 2022Sep 30, 2022-4.4%-4.3 ptsForm 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗
Q2 2022Jun 30, 2022-17.4%–Form 8-K (abbv-20220630xexhibit991.htm, filed 2022-07-29) ↗
Q1 2022Mar 31, 20221.5%–Form 8-K (abbv-20220331xexhibit991.htm, filed 2022-04-29) ↗
Q4 2021Dec 31, 20216.2%–Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗

Cite this data

StockData. (2026). AbbVie Lumigan/Ganfort (bimatoprost) (%), quarterly Q3 2021–Q4 2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/lumigan-us-rep-yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.